Germany's federal healthcare reimbursement program approved Delcath Systems' Chemosat with a Value 4 status.
Celsion was the center of a considerable amount of market buzz over the last year as the small biotech pushed a late-stage cancer drug through a Phase III liver cancer study. Its stock price tripled as investors rode a swell of enthusiasm that Celsion could beat the tough odds that face any small-cap company trying to make it all the way through an oncology program.
Celsion ($CLSN) grabbed $5 million in a development deal with China's Zhejiang Hisun Pharmaceutical, which has shown interest in advancing Celsion's ThermoDox product in China, Hong Kong and Macau.
A team at The Scripps Research Institute has developed a compound that reduced and even reversed fatty liver disease in animals, and had the added bonus of reducing plasma cholesterol levels.
At the beginning of this month ArQule shares tanked on the news that it had decided to shelve a late-stage study of tivantinib for non-small cell lung cancer after investigators concluded that the data pointed to a clear failure. But today the biotech got a little of its lost luster back with the news that it had agreed with regulators on the design of a new Phase III, landing a special protocol assessment on its program for liver cancer.
The German biotech 4SC AG says its experimental drug resminostat extended overall survival among advanced liver cancer patients by 8 months in Phase II when combined with Bayer's Nexavar.
Loss of the tiny RNA molecule miR-122 in liver cells may be all that it takes to cause full-blown liver cancer, according to a new Ohio State University study in mice. Restoring it, in turn, could slow the progression of the disease, scientists believe.
In a bid to dig deeper in the battle against liver cancer, scientists in Virginia have developed the first mouse model that shows some of the things a specific gene appears to be responsible for in advancing the deadly disease.
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, and is usually a result of hepatitis B or C infection, or cirrhosis of the liver. Diagnosis is generally through CT or MRI scanning, but biomarkers could make diagnosis simpler, quicker, more effective and less expensive.
Sanofi CEO Chris Viehbacher said that investigators would push ahead with the first human studies of the therapy next year.